Edition:
India

Karyopharm Therapeutics Inc (KPTI.OQ)

KPTI.OQ on NASDAQ Stock Exchange Global Select Market

18.64USD
13 Jul 2018
Change (% chg)

$0.05 (+0.27%)
Prev Close
$18.59
Open
$18.61
Day's High
$18.65
Day's Low
$18.20
Volume
121,571
Avg. Vol
269,317
52-wk High
$20.38
52-wk Low
$8.00

Chart for

About

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor... (more)

Overall

Beta: 4.16
Market Cap(Mil.): $551.05
Shares Outstanding(Mil.): 47.14
Dividend: --
Yield (%): --

Financials

BRIEF-Karyopharm Therapeutics Reports Q1 Loss Per Share Of $0.78

* KARYOPHARM REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS

10 May 2018

BRIEF-Karyopharm Therapeutics Says Offering Shares Of Common Stock With Aggregate Offering Price Of $125 Mln

* KARYOPHARM THERAPEUTICS INC SAYS OFFERING SHARES OF CO'S COMMON STOCK WITH AN AGGREGATE OFFERING PRICE OF $125 MILLION - SEC FILING Source text : (https://bit.ly/2w3kEIH) Further company coverage:

02 May 2018

BRIEF-Karyopharm Therapeutics Announces Proposed Public Offering Of Common Stock

* KARYOPHARM THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

02 May 2018

BRIEF-Karyopharm Announces Positive Top-Line Data From Phase 2b STORM Study Evaluating Selinexor In Patients With Penta-Refractory Multiple Myeloma

* KARYOPHARM ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2B STORM STUDY EVALUATING SELINEXOR IN PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA

01 May 2018

BRIEF-Karyopharm's Selinexor Receives Fast Track Designation From FDA

* KARYOPHARM'S SELINEXOR RECEIVES FAST TRACK DESIGNATION FROM FDA FOR THE TREATMENT OF PATIENTS WITH PENTA-REFRACTORY MULTIPLE MYELOMA

10 Apr 2018

BRIEF-Karyopharm Therapeutics Reports Q4 Loss Per Share Of $0.80

* KARYOPHARM REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS

15 Mar 2018

Biogen forecasts robust 2018, quarterly revenue beats on Spinraza sales

U.S. drugmaker Biogen Inc on Thursday reported fourth-quarter revenue that beat Wall Street estimates on higher sales for its drug Spinraza and forecast an upbeat 2018, sending its shares up 3 percent in premarket trading.

25 Jan 2018

BRIEF-Karyopharm Announces Agreement For Biogen To Acquire KPT-350

* KARYOPHARM ANNOUNCES AGREEMENT FOR BIOGEN TO ACQUIRE KPT-350 FOR THE TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE CONDITIONS

25 Jan 2018

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $37.53 +0.01
Roche Holding Ltd. (ROG.S) CHF232.70 --
Roche Holding Ltd. (RO.S) CHF237.80 --
AstraZeneca plc (AZN.L) 5,502.00 --

Earnings vs. Estimates